biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech at $1.0475

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Dec 31, 2022 4:04pm

102 Views

Post# 35198636

RE:RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

So the higher the Midatech stock price goes up from here to the closing of the arrangement the better.

I doubt it will go up too much (unless BTI does too). As the closing gets closer I would expect there to be less arbitrage opportunity.

<< Previous

Bullboard Posts

Next >>

Gold Flora's Gramlin holds court in California cannabis market